How Indian Hospitals Are Scaling Clinical Genomics Today
The rapid adoption of clinical genomics in India marks a transformative shift toward precision healthcare across hospital networks. However, technological capability alone cannot ensure successful implementation without clinical pathways. Therefore, leading healthcare institutions are actively integrating molecular testing into routine clinical practice. Consequently, oncologists and pathologists now collaborate closely to deliver tailored therapies for complex conditions.
The Expansion of Clinical Genomics in India
Today, precision medicine has moved significantly closer to routine tertiary care in major medical centers. In particular, molecular profiling provides actionable diagnostic insights that guide targeted therapeutic choices. Nevertheless, hospital leaders emphasize that scientific progress requires practical and accessible delivery models. Because patient demographics and economic capabilities vary, institutions cannot rely on a single adoption framework. Instead, tertiary centers are developing customized approaches based on institutional infrastructure and clinical volumes. Furthermore, industry partners now provide scientific support to assist hospitals at different maturity stages.
The Six Strategic Pillars for Precision Care
Delivering precision medicine requires a resilient healthcare delivery framework. Dr. Sunil Khetarpal identified six fundamental pillars to scale precision oncology across the country. These core pillars include diagnostic capacity, clinical integration, workforce development, affordability, data infrastructure, and strong governance. Furthermore, healthcare experts advocate for hub-and-spoke laboratory networks to bridge the urban-rural diagnostic divide. Consequently, smaller community hospitals can access advanced genomic testing without incurring massive capital expenses. In addition, molecular specialists must translate genomic findings into clear clinical guidance rather than isolated laboratory reports.
Pharmacogenomics and Population-Specific Evidence
Global genomic databases often lack adequate representation of the diverse Indian population. Therefore, Indian hospitals must generate localized clinical evidence to optimize drug safety and efficacy. For example, Hinduja Hospital researchers discovered that the NUDT15 variant predicts thiopurine toxicity better than TPMT. In contrast, international treatment guidelines originally focused exclusively on TPMT variants common in Caucasian populations. Notably, this discovery guided local clinical practice before global guidelines officially recognized the marker. Moreover, large initiatives like the Genome India Project provide critical reference genomes to identify population-specific variants.
Expanding Applications Beyond Oncology
Although oncology remains the primary specialty for precision medicine, molecular diagnostics now assists several other fields. For instance, clinicians routinely employ genomic panels to guide antiplatelet therapy in cardiovascular medicine. Similarly, genetic testing helps clinicians evaluate unexplained hypercoagulable states and inherited cardiomyopathy. Furthermore, specialists utilize targeted sequencing to screen carriers for spinal muscular atrophy and diagnose rare pediatric disorders. However, hospital executives urge physicians to exercise prudent clinical judgment rather than ordering indiscriminate genomic tests. Ultimately, artificial intelligence and multidisciplinary tumor boards can assist data interpretation, but clinicians must retain primary diagnostic authority.
Frequently Asked Questions
Q1: Why is NUDT15 testing crucial for Indian patients receiving thiopurine therapy?
The NUDT15 C415T variant strongly correlates with thiopurine-induced leukopenia in Indian populations, whereas TPMT variants occur rarely. Therefore, pre-treatment NUDT15 screening prevents severe myelosuppression and helps clinicians calibrate safe drug dosages.
Q2: How does the hub-and-spoke model improve access to genomic diagnostics?
The hub-and-spoke model connects regional tier-2 and tier-3 hospital spokes with centralized high-throughput genomic hubs. Consequently, peripheral centers obtain complex molecular testing without purchasing expensive sequencing platforms.
Q3: How does the Genome India Project benefit routine clinical care?
The project establishes an indigenous genomic reference catalogue representing diverse endogamous groups across the country. As a result, clinicians can accurately differentiate benign population variants from pathogenic disease-causing mutations.
References
- Hospitals at the heart of India’s genomics journey - ETHealthworld
- Shah SA, Paradkar M, Desai D, Ashavaid TF. Nucleoside diphosphate-linked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients. J Gastroenterol Hepatol. 2017;32(3):620-624.
- Department of Biotechnology, Government of India. GenomeIndia: Cataloguing the Genetic Diversity of India for Precision Medicine.
